Otsuka Holdings Co., Ltd.: Dermatitis, Atopic trials

The registry lists 12 Dermatitis, Atopic studies with Otsuka Holdings Co., Ltd. as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 1Phase 2 3Phase 3 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic DermatitisNot yet recruitingNCT07184645Phase 3
• A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic DermatitisNot yet recruitingNCT07173478Phase 3
• A Long-term Trial of OPA-15406 in Infants With Atopic DermatitisCompletedNCT05372653Phase 3Results posted
• Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic DermatitisCompletedNCT03961529Phase 3Results posted
• Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic DermatitisCompletedNCT03911401Phase 3Results posted
• Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndromeCompletedNCT03908970Phase 3Results posted
• Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic DermatitisCompletedNCT03018691Phase 2Results posted
• Study of OPA-15406 Ointment in Patients With Atopic DermatitisCompletedNCT02914548Phase 2Results posted
• A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic DermatitisCompletedNCT02068352Phase 2Results posted
• To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With ADCompletedNCT05667623Phase 3
• To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with ADCompletedNCT05650320Phase 3
• A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic DermatitisCompletedNCT01702181Phase 1